CD19 CAR T-cell therapy in autoimmune disease–A case series with follow-up

Resetting aberrant autoimmunity in autoimmune diseases such as systemic lupus erythematosus, idiopathic inflammatory myositis, and systemic sclerosis through deep depletion of B cells is a potential strategy for achieving sustained drug-free remission. Fifteen patients with these diseases received a single infusion of CD19 CAR-T cells after preconditioning with fludarabine and cyclophosphamide. In this case series, CD19 CAR T-cell transfer appeared to be achievable, safe, and efficacious in three different autoimmune diseases.